Richard Wang

Richard Wang has held a number of roles in the financial and medical industries. Richard began their career in 2013 as a Pediatric Oncology & Biochemistry researcher at The National Institutes of Health. In 2016, they joined Morgan Stanley as an Investment Banking analyst. In 2017, they moved to The D. E. Shaw Group, where they held roles in Global Special Situations Arbitrage Investing and Corporate Development & New Ventures. In 2019, they joined Bird as a Corporate Development & Strategy analyst. Most recently, in 2022, they became the Head of Capital Markets & Corporate Development at AtoB.

Richard Wang attended Thomas Jefferson High School for Science and Technology, where they studied Biotechnology & Life Sciences and Pediatric Oncology. Richard then went on to Cornell University, where they studied Economics and Political Philosophy & Critical Theory.